Physician-executive with 30+ years across clinical practice, biotech, and digital health joins board to advance Paradigm’s mission and growth
SAN DIEGO, June 10, 2026 — Paradigm Clinical Research, a clinical research site organization, announced today the appointment of Greg Licholai, MD, to its board of directors. Dr. Licholai currently serves as Chief Medical Officer at Syneos Health.
Dr. Licholai
is one of the most broadly experienced physician-executives in the
biopharmaceutical industry, with more than three decades of leadership across
clinical development and healthcare innovation. He has shaped clinical
development strategies at some of the world's leading organizations, guided
companies through critical stages of growth, leveraged data to drive healthcare
intelligence, and contributed to the direction of the industry as both an
executive and advisor.
"I
have long admired Greg's ability to operate at the intersection of science,
strategy, and execution. He understands this industry from every angle: as a
physician, as an executive, as a founder, and as an advisor to the regulators
who shape it. As we expand our footprint and take on increasingly complex
programs for sponsors, having a board member who has navigated clinical
development, scaled organizations, and driven healthcare innovation at the
highest levels brings invaluable perspective to everything we are building.
Greg shares our belief that consistency, reliability, and patient experience
will define the next generation of clinical research, and his joining our board
reflects the ambition and momentum behind where Paradigm is headed," said Kurt Mussina, CEO of Paradigm
Clinical Research.
Dr.
Licholai’s career
includes executive roles at some of the industry's most prominent
organizations: Chief Medical and Innovation Officer at ICON plc; President and
Chief Scientific Officer at Castle Creek Pharmaceuticals; President of
Elpidera, a division of Moderna Therapeutics; Senior Vice President at
Quintiles, now IQVIA; Chief Operating Officer at Proteostasis; Vice President
and Partner at McKinsey & Company, where he led the healthcare data service
line; and leadership roles at Amicus Therapeutics and Medtronic. He also co-founded
Immunome, Inc., a clinical-stage oncology company, and has advised venture
capital firms throughout his career.
A recognized
expert in digital health innovation, Dr. Licholai co-founded the Yale Center
for Digital Health and has lectured at Yale School of Management for 12 years
and was visiting lecturer at Harvard Business School. He writes regularly for Forbes
on artificial intelligence, digital medicine, and drug development, and has
advised the FDA's Center for Devices and Radiological Health and the Clinical
Trials Transformation Initiative on the evaluation and adoption of emerging
health technologies. Dr.
Licholai earned his MD from Yale School of Medicine and his MBA from Harvard
Business School.
"I am
pleased to join the Paradigm board at a pivotal moment in the company's growth.
What sets Paradigm apart is the combination of centralized operations and
governance across wholly owned sites, which delivers the consistency and
quality sponsors depend on, and a network of principal investigators embedded in
their communities, which brings genuine patient trust, enrollment access, and
population diversity. Sponsors and CROs need the consistent, high-quality
patient-oriented clinical research results that Paradigm can help deliver," said Dr. Licholai.
About
Paradigm Clinical Research Paradigm Clinical Research
is a clinical research site organization renowned for its trusted client
relationships and exceptional patient experience, supporting phase I–IV
programs across metabolic disease, dermatology, pulmonology, neurology and
psychiatry, ophthalmology, and vaccines and infectious disease. The company
operates wholly owned clinical trial sites with centralized governance and infrastructure
and collaborates with 40+ board-certified principal investigators embedded in
communities, providing access to diverse and specialty patient populations for
sponsors and CRO partners.
Over the past two years,
Paradigm has doubled its site footprint through a de novo growth strategy and
expanded its principal investigator network across geographies and therapeutic
indications, all while maintaining a patient experience score of 98%, a net
promoter score of 96, and a consistent record of meeting enrollment commitments
and study timelines. Additional information is available at www.paradigm-research.com.
